JP6012468B2 - 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール - Google Patents

抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール Download PDF

Info

Publication number
JP6012468B2
JP6012468B2 JP2012531448A JP2012531448A JP6012468B2 JP 6012468 B2 JP6012468 B2 JP 6012468B2 JP 2012531448 A JP2012531448 A JP 2012531448A JP 2012531448 A JP2012531448 A JP 2012531448A JP 6012468 B2 JP6012468 B2 JP 6012468B2
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012531448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506639A5 (en:Method
JP2013506639A (ja
Inventor
ココトス、ジョージ
ヨハンセン、ベリト
マグリオティ、ビクトリア
ツァコス、マイケル
Original Assignee
アヴェクシン エーエス
アヴェクシン エーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴェクシン エーエス, アヴェクシン エーエス filed Critical アヴェクシン エーエス
Publication of JP2013506639A publication Critical patent/JP2013506639A/ja
Publication of JP2013506639A5 publication Critical patent/JP2013506639A5/ja
Application granted granted Critical
Publication of JP6012468B2 publication Critical patent/JP6012468B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012531448A 2009-10-02 2010-10-01 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール Expired - Fee Related JP6012468B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24833809P 2009-10-02 2009-10-02
US61/248,338 2009-10-02
PCT/EP2010/064687 WO2011039365A1 (en) 2009-10-02 2010-10-01 Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles

Publications (3)

Publication Number Publication Date
JP2013506639A JP2013506639A (ja) 2013-02-28
JP2013506639A5 JP2013506639A5 (en:Method) 2013-08-15
JP6012468B2 true JP6012468B2 (ja) 2016-10-25

Family

ID=43221889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012531448A Expired - Fee Related JP6012468B2 (ja) 2009-10-02 2010-10-01 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール

Country Status (11)

Country Link
US (2) US9597318B2 (en:Method)
EP (2) EP3431084A1 (en:Method)
JP (1) JP6012468B2 (en:Method)
KR (4) KR20120089701A (en:Method)
CN (3) CN104892542B (en:Method)
AU (1) AU2010302584B2 (en:Method)
CA (1) CA2782797C (en:Method)
DK (1) DK2482815T3 (en:Method)
IN (1) IN2012DN02982A (en:Method)
NO (1) NO2482815T3 (en:Method)
WO (1) WO2011039365A1 (en:Method)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3431084A1 (en) 2009-10-02 2019-01-23 Avexxin AS Antiinflammatory 2-oxothiazoles
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) * 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
CA2899137C (en) * 2013-01-29 2021-07-13 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
GB201307331D0 (en) * 2013-04-23 2013-05-29 Norwegian Univ Sci & Tech Ntnu Compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB2550363A (en) * 2016-05-16 2017-11-22 Avexxin As Compound
CN109789111B (zh) 2016-09-21 2021-11-16 埃维克辛公司 药物组合物
US20190275010A1 (en) * 2016-11-04 2019-09-12 Avexxin As Combination therapy comprising a thiazole and a secosteroid to treat skin conditions
EP3534955A1 (en) * 2016-11-04 2019-09-11 Avexxin AS Combination therapy comprising a thiazole and a corticosteroid to treat skin conditions
JP7169584B2 (ja) * 2018-01-30 2022-11-11 公立大学法人横浜市立大学 オーキシン生合成阻害活性を有する新規化合物、その製造方法及びその用途
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone
GB202117609D0 (en) 2021-12-06 2022-01-19 Coegin Pharma Ab 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
CN115028597B (zh) * 2022-04-29 2024-03-26 闽都创新实验室 一种tempo连续脱氢环化制备苯并恶唑类衍生物的方法和应用
WO2025125241A1 (en) 2023-12-15 2025-06-19 Coegin Pharma Ab Pharmaceutical composition

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894152A (en) * 1969-09-15 1975-07-08 Innothera Lab Sa Use of (thienyl-3)(3-N-morpholine-propy)ketone
FR2062868B1 (en:Method) 1969-09-15 1973-08-10 Innothera Lab Sa
DE2063901A1 (en) 1970-12-28 1972-07-20 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Phenylalkylaminoalkylthiazoles - as antiphlogistics
US5177215A (en) 1984-11-12 1993-01-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic compounds and pharmaceutical use thereof
PH22520A (en) 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
ZA894913B (en) 1988-07-12 1990-03-28 Ici Pharma Heterocyclic compounds
US5272986A (en) 1991-05-13 1993-12-28 British Gas Plc Towing swivel for pipe inspection or other vehicle
TW263504B (en:Method) 1991-10-03 1995-11-21 Pfizer
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5268395A (en) 1992-10-13 1993-12-07 Martin Marietta Energy Systems, Inc. Microcellular carbon foam and method
JP3345476B2 (ja) * 1993-05-18 2002-11-18 株式会社東芝 有機非線形光学材料
US5569655A (en) * 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
WO1996003392A1 (en) 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US6214994B1 (en) * 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
TW438786B (en) 1995-03-28 2001-06-07 Nippon Zoki Pharmaceutical Co Novel benzothiazole derivatives
WO1996036617A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO1996039399A1 (en) * 1995-06-06 1996-12-12 Pharm-Eco Laboratories, Inc. Stereoselective method for synthesizing dolaphenine
DE19638408A1 (de) * 1996-09-19 1998-03-26 Merckle Gmbh 1-Substituierte 3-Acyl-4,5-dimethylpyrrol-2-carbonsäuren und 3-Acylindol-2-carbonsäuren sowie ihre Derivate als Hemmstoffe der cytosolischen Phospholipase A¶2¶
WO1998032741A1 (en) * 1997-01-29 1998-07-30 Zeneca Limited Inhibitors of farnesyl protein transferase
EP0867437B1 (en) 1997-03-14 2002-11-13 Koninklijke Philips Electronics N.V. "Method of preparing a thiophene-containing or furan -containing conjugated compound and precursor compound used therein".
AU730364B2 (en) * 1997-09-23 2001-03-08 Bristol-Myers Squibb Company Selective cPLA2 inhibitors
JPH11255700A (ja) 1998-03-12 1999-09-21 Taiho Ind Co Ltd アセチルアセトン系金属錯体及びその合成法、並びにそれを用いた有機多層型エレクトロルミネッセンス素子
BR9912907A (pt) 1998-08-11 2001-05-08 Bayer Agrochem Kk Pirazóis nematicidas
SE9804212D0 (sv) * 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
CA2409821A1 (en) 2000-05-18 2002-11-18 Yoshikazu Ikeda Novel benzothiophene derivatives
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
US6795725B2 (en) 2001-12-18 2004-09-21 3Pcm Company Method and apparatus for endoscopic measurement of myoelectrical activity from the stomach and other hollow intra-abdominal organs
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
KR20050025189A (ko) * 2002-07-27 2005-03-11 아스트라제네카 아베 화학 화합물
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US6930391B2 (en) 2002-08-27 2005-08-16 Intel Corporation Method for alloy-electroplating group IB metals with refractory metals for interconnections
CA2501575A1 (en) * 2002-10-08 2004-04-22 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
JP2006514102A (ja) * 2002-11-07 2006-04-27 アストラゼネカ アクチボラグ ２−オキソ−エタンスルホンアミド誘導体
ES2321519T3 (es) 2003-09-18 2009-06-08 Tokuyama Corporation Compuesto de cromeno.
TWI336697B (en) 2003-09-19 2011-02-01 Solvay Pharm Bv Thiazole derivatives as cannabinoid receptor modulators
JP4226438B2 (ja) 2003-10-23 2009-02-18 エヌ・ティ・ティ・コムウェア株式会社 パック装置およびセンステーブル装置、ならびに移動軌跡算出方法、移動軌跡算出プログラム、その記録媒体
US20050137243A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
JP2005343889A (ja) * 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
KR101242310B1 (ko) 2004-05-17 2013-03-12 오츠카 세이야쿠 가부시키가이샤 티아졸 화합물 및 그의 용도
US7178364B2 (en) 2004-07-22 2007-02-20 Shapiro Kristen M Personal adornment
WO2006016218A1 (en) * 2004-08-03 2006-02-16 Pfizer Japan Inc. Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists
WO2006057503A1 (en) * 2004-11-25 2006-06-01 Lg Life Sciences, Ltd. NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
LT2455382T (lt) * 2005-12-13 2017-02-10 Incyte Holdings Corporation Heteroarilu pakeisti pirolo[2,3-b]piridinai ir prolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
EP1983994B1 (en) 2006-02-17 2015-09-30 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
WO2008013963A2 (en) * 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
DK2116530T3 (da) * 2007-02-26 2013-01-28 Santen Pharmaceutical Co Ltd Nyt pyrrolderivat, der har en ureidgruppe og en aminobonylgruppe som substituenter
CN101627007A (zh) * 2007-03-05 2010-01-13 弗·哈夫曼-拉罗切有限公司 用作食欲肽拮抗剂的氨基酰胺
CA2689148A1 (en) * 2007-05-31 2008-12-11 The Scripps Research Institute Tricyclic inhibitors of fatty acid amide hydrolase
EP3431084A1 (en) 2009-10-02 2019-01-23 Avexxin AS Antiinflammatory 2-oxothiazoles
CN103228641A (zh) 2010-11-22 2013-07-31 日立化成株式会社 稀土类金属络合物
CA2899137C (en) * 2013-01-29 2021-07-13 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
GB201413695D0 (en) * 2014-08-01 2014-09-17 Avexxin As Compound

Also Published As

Publication number Publication date
CA2782797C (en) 2018-08-07
CN102647984B (zh) 2015-03-25
US20110136879A1 (en) 2011-06-09
US10370344B2 (en) 2019-08-06
KR20190082985A (ko) 2019-07-10
KR20120089701A (ko) 2012-08-13
AU2010302584A1 (en) 2012-05-24
EP2482815A1 (en) 2012-08-08
HK1197551A1 (zh) 2015-01-23
KR20180114228A (ko) 2018-10-17
KR101907535B1 (ko) 2018-10-15
HK1210157A1 (en) 2016-04-15
KR20170038941A (ko) 2017-04-07
IN2012DN02982A (en:Method) 2015-07-31
AU2010302584B2 (en) 2015-09-10
EP3431084A1 (en) 2019-01-23
KR101997163B1 (ko) 2019-07-08
WO2011039365A1 (en) 2011-04-07
DK2482815T3 (en) 2018-06-06
CN102647984A (zh) 2012-08-22
US9597318B2 (en) 2017-03-21
CN103772312B (zh) 2016-08-17
CN104892542A (zh) 2015-09-09
EP2482815B1 (en) 2018-05-02
NO2482815T3 (en:Method) 2018-09-29
CA2782797A1 (en) 2011-04-07
CN104892542B (zh) 2018-01-26
CN103772312A (zh) 2014-05-07
JP2013506639A (ja) 2013-02-28
US20170166539A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
JP6012468B2 (ja) 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール
US10259801B2 (en) Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds
EP1921074A1 (en) Thiazole derivative
CN107074840B (zh) 用于治疗炎性疾病和过度增殖性疾病的具有作为cPLA2抑制剂的活性的2-氧代噻唑化合物
JP5048199B2 (ja) ジフェニルエチレン化合物の新規複素環式類似体
US5688821A (en) Unsaturated fatty acyl derivatives of 2-aminothiazoleacetic acid and their salts as inhibitors of phospholipase A2 derived from human sources
JP3591514B2 (ja) 複素環誘導体
AU2015268638B2 (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
JP2001240593A (ja) 高トリグリセリド血症治療薬及び抗肥満薬
HK1197551B (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
JP2004250460A (ja) 複素環誘導体
JPWO2001014350A1 (ja) 置換ベンジルチアゾリジン−２，４−ジオン誘導体
JPWO2006080407A1 (ja) Ｐｐａｒ活性化化合物
JPWO1999011255A1 (ja) ペルオキシソーム増殖薬活性化受容体制御剤
JPH05194221A (ja) 抗脂血剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160920

R150 Certificate of patent or registration of utility model

Ref document number: 6012468

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees